Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.37 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | TK2 | O00142 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20394037 | 0.94 | TK1 (0.36) | TK1NT5MBCHERNASE1ABCG2 | |
| SCHEMBL20394003 | 0.87 | TK1 (0.36) | TK1NT5MBCHERNASE1 | |
| SCHEMBL20394002 | 0.87 | TK1 (0.36) | TK1NT5MBCHERNASE1 | |
| SCHEMBL23152969 | 0.83 | TK2 (0.39) | TK1NT5MBCHERNASE1TK2 | |
| SCHEMBL20394047 | 0.82 | TK1 (0.39) | TK1 | |
| SCHEMBL23152967 | 0.82 | TK1 (0.38) | TK1NT5MBCHERNASE1TK2 | |
| SCHEMBL14946306 | 0.82 | TK1 (0.44) | TK1NT5MBCHERNASE1TK2 | |
| SCHEMBL11981102 | 0.82 | TK1 (0.44) | TK1NT5MBCHERNASE1TK2 | |
| SCHEMBL16648575 | 0.81 | TK1 (0.38) | TK1NT5MBCHERNASE1TK2 | |
| SCHEMBL23152977 | 0.81 | TK1 (0.41) | TK1NT5MBCHERNASE1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2021-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961269-B2 | Bridged nucleic acid GuNA, method for producing same, and intermediate compound | POLRMT, POLM, NSUN2 | TK1 572/4885NT5M 4501/4885BCHE 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.